AbbVie Inc (ABBV)vsPhreesia Inc (PHR)
ABBV
AbbVie Inc
$207.86
+2.51%
HEALTHCARE · Cap: $358.55B
PHR
Phreesia Inc
$9.57
-5.90%
HEALTHCARE · Cap: $581.50M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 12971% more annual revenue ($62.82B vs $480.59M). ABBV leads profitability with a 5.8% profit margin vs 0.5%. ABBV trades at a lower P/E of 98.9x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PHR
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$207.86
$39.53 premium
Margin of Safety
+77.8%
Fair Value
$56.21
Current Price
$9.57
$46.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
15.9% revenue growth
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.8% — below average capital efficiency
0.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : PHR
The strongest argument for PHR centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : PHR
The primary concerns for PHR are EPS Growth, Market Cap, Return on Equity. A P/E of 239.3x leaves little room for execution misses. Thin 0.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while PHR is a growth play — different risk/reward profiles.
PHR carries more volatility with a beta of 0.89 — expect wider price swings.
PHR is growing revenue faster at 15.9% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 43/100) and 12.4% revenue growth. PHR offers better value entry with a 77.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?